http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Therapeutic Mechanisms of Human Adipose-Derived Mesenchymal Stem Cells in a Rat Tendon Injury Model
Lee, Sang Yoon,Kwon, Bomi,Lee, Kyoungbun,Son, Young Hoon,Chung, Sun G. AMERICAN JOURNAL OF SPORTS MEDICINE 2017 AMERICAN JOURNAL OF SPORTS MEDICINE - Vol.45 No.6
<P>Clinical Relevance: In tendon injury, MSCs can enhance tendon healing by secreting their own protein and have potential as a therapeutic option in human tendinopathy.</P>
Lee, Jiwon M,Ahn, Yo Han,Kang, Hee Gyung,Ha, I I Soo,Lee, Kyoungbun,Moon, Kyung Chul,Lee, Joo Hoon,Park, Young Seo,Cho, Yong Mee,Bae, Jun-Seok,Kim, Nayoung K D,Park, Woong-Yang,Cheong, Hae Ii Springer International 2015 Pediatric nephrology Vol.30 No.9
<P>Nephronophthisis 13 (NPHP 13) is associated with mutations in the WDR19 gene, which encodes for a protein in the intraflagellar transport complex. Herein, we describe six additional cases accompanied by Caroli syndrome or disease.</P>
Modified Rat Hepatocellular Carcinoma Models Overexpressing Vascular Endothelial Growth Factor
Choi, Jin Woo,Cho, Hye Rim,Lee, Kyoungbun,Jung, Jae Kyung,Kim, Hyo-Cheol Elsevier 2018 Journal of Vascular and Interventional Radiology Vol.29 No.11
<P><B>Abstract</B></P> <P><B>Purpose</B></P> <P>To compare tumor vascularity in 4 types of rat hepatocellular carcinoma (HCC) models: N1S1, vascular endothelial growth factor (VEGF)-transfected N1S1 (VEGF-N1S1), McA-RH7777, and VEGF-transfected McA-RH7777 (VEGF-McA-RH777) tumors.</P> <P><B>Materials and Methods</B></P> <P>The N1S1 and McA-RH7777 cell lines were transfected with expression vectors containing cDNA for rat VEGF. Eighty-eight male Sprague–Dawley rats (weight range, 400–450 g) were randomly divided into 4 groups (ie, 22 rats per model), and 4 types of tumor models were created by using the N1S1, VEGF-N1S1, McA-RH7777, and VEGF-McA-RH777 cell lines. Tumor vascularity was evaluated by perfusion computed tomography (CT), enzyme-linked immunosorbent assay of VEGF, CD34 staining, angiography, and Lipiodol transarterial embolization. Intergroup discrepancies were evaluated by Kruskal–Wallis test.</P> <P><B>Results</B></P> <P>Arterial perfusion (<I>P</I> < .001), portal perfusion (<I>P</I> = .015), total perfusion (<I>P</I> < .001), tumor VEGF level (<I>P</I> = .002), and microvessel density (MVD; <I>P</I> = .007) were significantly different among groups. VEGF-McA-RH7777 tumors showed the greatest arterial perfusion (46.7 mL/min/100 mL ± 15.5), total perfusion (60.7 mL/min/100 mL ± 21.8), tumor VEGF level (3,376.7 pg/mL ± 145.8), and MVD (34.5‰ ± 7.5). Whereas most tumors in the N1S1, VEGF-N1S1, and McA-RH7777 groups showed hypovascular staining on angiography and minimal Lipiodol uptake after embolization, 5 of 6 VEGF-McA-RH7777 tumors (83.3%) presented hypervascular tumor staining and moderate to compact Lipiodol uptake.</P> <P><B>Conclusions</B></P> <P>McA-RH7777 tumors were more hypervascular than N1S1 tumors, and tumor vascularity was enhanced further by VEGF transfection. Therefore, the VEGF-McA-RH7777 tumor is recommended to mimic hypervascular human HCC in rats.</P>
Kim, Yikwon,Kang, MeeJoo,Han, Dohyun,Kim, Hyunsoo,Lee, KyoungBun,Kim, Sun-Whe,Kim, Yongkang,Park, Taesung,Jang, Jin-Young,Kim, Youngsoo American Chemical Society 2016 JOURNAL OF PROTEOME RESEARCH Vol.15 No.1
<P>Intraductal papillary mucinous neoplasm (IPMN) is a common precursor of pancreatic cancer (PC). Much clinical attention has been directed toward IPMNs due to the increase in the prevalence of PC. The diagnosis of IPMN depends primarily on a radiological examination, but the diagnostic accuracy of this tool is not satisfactory, necessitating the development of accurate diagnostic biomarkers for IPMN to prevent PC. Recently, high-throughput targeted proteomic quantification methods have accelerated the discovery of biomarkers, rendering them powerful platforms for the evolution of IPMN diagnostic biomarkers. In this study, a robust multiple reaction monitoring (MRM) pipeline was applied to discovery and verify IPMN biomarker candidates in a large cohort of plasma samples. Through highly reproducible MRM assays and a stringent statistical analysis, 11 proteins were selected as IPMN marker candidates with high confidence in 184 plasma samples, comprising a training (n = 84) and test set (n = 100). To improve the discriminatory power, we constructed a six-protein panel by combining marker candidates. The multimarker panel had high discriminatory power in distinguishing between IPMN and controls, including other benign diseases. Consequently, the diagnostic accuracy of IPMN can be improved dramatically with this novel plasma-based panel in combination with a radiological examination.</P>
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases
( Hyeki Cho ),( Yuri Cho ),( Eun Ju Cho ),( Jeong Hoon Lee ),( Su Jong Yu ),( Kook Hwan Oh ),( Kyoungbun Lee ),( Syifa Mustika ),( Jung Hwan Yoon ),( Yoon Jun Kim ) 대한간학회 2016 Clinical and Molecular Hepatology(대한간학회지) Vol.22 No.2
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy. (Clin Mol Hepatol 2016;22:286-291)
항암화학 치료를 통해 병리학적 완전 관해에 이른 절제 불가능한 국소 진행성 간내담관암
양효준 ( Hyo Jun Yang ),류지곤 ( Ji Kon Ryu ),백우현 ( Woo Hyun Paik ),이상협 ( Sang Hyub Lee ),김용태 ( Yong-tae Kim ),이경분 ( Kyoungbun Lee ) 대한췌담도학회 2017 대한췌담도학회지 Vol.22 No.4
식후 소화불량 및 복통을 주소로 내원한 54세 여자 환자가 영상 검사 및 간조직검사를 통해 절제 불가능한 국소 진행성 간내담관암으로 진단을 받았다. 환자는 진단 이후 총 40주기의 gemcitabine 및 cisplatin 병합 항암화학요법 이후 수술적 절제가 가능하다고 판단되어 확대 간우엽절제술 및 간문맥 구역절제술을 시행 받은 뒤 병리학적 완전 관해로 판정되어 추가적 치료 없이 경과를 관찰하며 6년 이상 장기생존 중이다. 본 증례를 통해 절제가 불가능한 국소 진행성 간내담관암 또한 적극적인 항암화학요법을 통해 병리학적 완전 관해에 이르러 장기생존을 도모할 수 있음을 알게 되었으며, 향후 이와 비슷한 환자의 치료에 있어 최근 연구되고 있는 다양한 방법들을 이용한 적극적인 치료가 필요하다고 생각된다. A 54-year-old female with postprandial dyspepsia and abdominal pain was diagnosed as locally advanced unresectable intrahepatic cholangiocarcinoma by radiologic imaging studies resulting in invasion to bilateral main bile duct and right portal vein. The patient underwent extended right hepatectomy and portal vein resection after gemcitabine and cisplatin combined chemotherapy for a total of 40 cycles after the diagnosis. Final pathology showed, followed by pathological complete remission, without any residual cancer cell. The patient has survived for over 6 years without any evidence of recurrence. This case suggests that locally advanced intrahepatic cholangiocarcinoma, which can’t be resected, was also proved to be capable of pathological complete remission with active chemotherapy, and long-term survival could be achieved. Therefore, active multidisciplinary approach and patient-oriented treatments using various methods should be considered for locally advanced unresectable intrahepatic cholangiocarcinoma. Korean J Pancreas Biliary Tract 2017;22(4):188-192